Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06558097 · ClinicalTrials.gov registry record · Phase 1
Safety, Tolerability, and Pharmacokinetics of XXB750 in Healthy Participants
A Phase 1 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 77
- Enrollment target
NCT06558097 is a Phase 1 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 77 participants.
The verdict
NCT06558097, a Phase 1 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 77 participants
- Enrollment target
Study Summary
This study was a randomized, participant and investigator-blinded, placebo-controlled, single-ascending dose study, consisting of 9 sequential dose cohorts (1 mg, 3 mg, 10 mg, 30 mg, 60 mg, 120 mg, 240 mg, 450 mg and 600 mg) and a Japanese ethnic sensitivity cohort (240 mg dose)
Interventions
- OTHER Placebo
- DRUG XXB750
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 77 participants |
| Start Date | 2020-07-29 |
| Est. Completion | 2023-03-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06558097
The ClinicalTrials.gov registry entry for NCT06558097 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 77 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT06558097 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06558097 about?
NCT06558097 is a clinical study titled "Safety, Tolerability, and Pharmacokinetics of XXB750 in Healthy Participants". This study was a randomized, participant and investigator-blinded, placebo-controlled, single-ascending dose study, consisting of 9 sequential dose cohorts (1 mg, 3 mg, 10 mg, 30 mg, 60 mg, 120 mg, 240 mg, 450 mg and 600 mg) and a Japanese ethnic sensitivity cohort (240 mg dose)
What is the current status of trial NCT06558097?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 77 participants. The study started on 2020-07-29. Estimated completion is 2023-03-31.
What interventions are being tested in trial NCT06558097?
The interventions under investigation include: Placebo (OTHER), XXB750 (DRUG).
Who is sponsoring clinical trial NCT06558097?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.